Tela Bio, Inc. · NASDAQ:TELA
Tela Bio — Q1 2023 Earnings Presentation
22 slides from Tela Bio's earnings presentation, May 11, 2023
Slide 1: Investor Presentation
INVESTOR PRESENTATION May 2025
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this document, including but not limited to statements regarding possible
Slide 3: Our Mission
We provide innovative soft- tissue reconstruction solutions Our Mission that optimize clinical outcomes by prioritizing the Preservation and Restoration of the patient’s own anatomy. 3
Slide 4: TELA Bio, Inc.
TELA Bio, Inc. Advanced reinforced tissue matrix portfolio supported by compelling clinical evidence $2.6B US market opportunity1 – still in early stages of growth Driving commercial adoption with targeted direct-sales approach Recent product launches in growing markets: robotic hernia surgery, plas
Slide 5: Product Adoption Since Launch
Product Adoption Since Launch 69,000+ 40+ 6,000+ OviTex Reinforced Tissue Matrix Published or Presented Works Hospitals Covered by (RTM) Implantations Globally GPO Access ~ 15,000 OviTex PRS Implantations Globally 5
Slide 6: Reinforced Tissue Matrix
REINFORCED TISSUE MATRIX @TELABIO ION.
Slide 7: US Hernia Surgery Market $1.8B
US Hernia Surgery Market ~$1.8 Billion Annual Opportunity Annual Procedures1 Complex, Moderate Ventral / $630M Abdominal Wall Reconstruction ~105,000 Robotic / Minimally Invasive Surgery (MIS) $590M Simple Ventral Hernia Repair ~395,000 Opportunity within the 2 $1.8B $540M Inguinal Hernia Repair ~64
Slide 8: OviTex Reinforced Tissue Matrix
OviTex Reinforced Tissue Matrix A more Natural Hernia Repair OviTex Core OviTex 1S OviTex 2S OviTex LPR OviTex IHR 4-layer device 6-layer device 8-layer device 4-layer device 4-layer and 3-layer device No smooth sides 1 smooth side 2 smooth sides 1 smooth side No smooth sides Robot Compatible1: Yes
Slide 9: Need for Alternative to Permanent Synthetic Mesh
Need for Alternative to Permanent Synthetic Mesh 59% Of surgeons agree that use of permanent synthetic mesh puts patients at long-term risk of complications1 3 of 4 Hernia patients want proactive control in their care2 Product liability lawsuits relating to permanent synthetic hernia repair (as of N
Slide 10: Consistently Low Recurrence Rates
Consistently Low Recurrence Rates Backed by 8+ years of clinical experience and 40+ published or presented works Source: Refer to “Clinical References” in this presentation. * Indicates one or more surgeons are paid consultants of TELA Bio, Inc. 10
Slide 11: Favorable Results of OviTex in Ventral Hernia Repair
Favorable Results of OviTex in Ventral Hernia Repair Comparisons to synthetic mesh and leading first generation biologics Parker et al.3 Sivaraj et al.2 Total enrolled patients 50 OviTex 50 Polypropylene 36 OviTex 51 Strattice 17 Permacol 37 Surgimend 28.6 months 34.6 months 58.4 months 37.5 months
Slide 12: Positive 24-month BRAVO Results In Ventral Hernia
Positive 24-month BRAVO Results In Ventral Hernia OviTex performance contextualized alongside contemporaneous publications for leading competitive products DeNoto et al. (BRAVO)4 Harris et al. (PRICE) 11 Roth et al.12 Hope et al. (ATLAS)13 83 Ventralight ST or Total enrolled patients 92 OviTex 82 St
Slide 13: Hernia Market Evolution
Hernia Market Evolution TELA Bio positioned to grow from a market shift towards resorbable and more “natural repair” solutions as an alternative to traditional Permanent Synthetics or Biologics 2013 <1% Robotic Procedures (Px) Sales Market Share 2018 7% Robotic Px 2021 12% Robotic Px 2023 14% Roboti
Slide 14: OviTex PRS Reinforced Tissue Matrix
UVITEX PRS REINFORCED TISSUE MATRIX @TELABIO’ SCIENCE. VALUE. INNOVATION. 44
Slide 15: US Plastic & Reconstructive Surgery Market $700M
US Plastic & Reconstructive Surgery Market ~$800 Million Annual Opportunity Surgeons use products to reinforce soft Cosmetic Plastic & tissue during various reconstructive Reconstructive Surgery surgeries1, including: Head and neck surgery Chest wall reconstruction $700M 2 Pelvic reconstruction Extr
Slide 16: OviTex PRS
OviTex PRS An innovative reinforced tissue matrix designed to Specifically improve outcomes by facilitating fluid management and designed for plastic controlling degree and direction of stretch and reconstructive surgery Product Features: Layers composed of biologic building block retain biologicall
Slide 17: Leading-edge atraumatic hernia mesh fixation devices
Leading-edge atraumatic hernia mesh fixation devices Designed to minimize complications for patient safety and comfort 17
Slide 18: LIQUIFIX FIX8 & LIQUIFIX Precision
LIQUIFIX FIX8 & LIQUIFIX Precision Atraumatic liquid fixation devices Reduce the need for penetrating mechanical fixation for inguinal and femoral hernia repair Provide precise, controlled adhesive application Addresses an unmet need in the market, less damage to tissue Designed to minimize the risk
Slide 19: Driving Revenue Growth
Driving Revenue Growth Sales Force Size X Rep Productivity X Product Portfolio X GPO Access X Clinical Experience = $ SALES 2021 Playbook90 BRAVO 24-month 40-45 reps / training (new data: 2.6% 5 TB Ltd. reps) & ongoing, recurrence intensive product >1,600 hospitals training 40+ published or 2022 61
Slide 20: Quarterly Revenue and Gross Margin
Quarterly Revenue and Gross Margin $69.3M, +19% $58.5M, +41% $20 +26% +12% +4% 80% +46% +39% +11% +35% $15 $41.4M, +41% +39% 75% Revenue ($M) Gross Margin +39% +45% +46% +38% $10 +40% 70% $5 65% $0 60% 1Q22 2Q22 3Q22 4Q22 1Q23 2Q23 3Q23 4Q23 1Q24 2Q24 3Q24 4Q24 1Q25 Revenue Gross Margin 19 20
Slide 21: Q1 2025 Performance
Q1 2025 Performance 68% Gross Margin $42.8M $19M Cash and Cash Quarterly revenue of $18.5M, Delivering Revenue Equivalents at March 31, 2025 growing 12% over corresponding period of 2024 Growth and Strong Margin with The Company implemented cost- cutting measures in Q3 2024, which Continuing are exp
Slide 22: Clinical References
Clinical References 1. Ankney, C.; Banaschak, C.; Sowers, B.; Szotek, P. Minimizing Retained Foreign Body in Hernia Repair Using a Novel Technique: Reinforced Biologic Augmented Repair (ReBAR). J Clin Medical Res 2021, doi:10.37191/mapsci-2582-4333-3(4)-073. 2. Sivaraj, D.; Henn, D.; Fischer, K.S.;